Eligible patients with previously untreated limited-stage SCLC received one cycle of etoposide plus cisplatin ( intravenous etoposide 100 mg/m ( 2 ) on days 1-3 ; intravenous cisplatin 80 mg/m ( 2 ) on day 1 ) plus AHTRT ( 1.5 Gy twice daily , 5 days a week , total 45 Gy over 3 weeks ) .